What Is Hemopressin? Definition and What Research Reports

Definition

Hemopressin is the name given to a short peptide originally isolated as a fragment of the alpha chain of hemoglobin. It belongs to a family of so-called "non-classical" or "hidden" neuropeptides — sequences that are not produced from a dedicated precursor gene in the way that classical neuropeptides are, but are instead generated by proteolytic processing of an abundant cytosolic or blood protein, in this case hemoglobin. A review of these hemoglobin-derived sequences discussed hemopressin alongside other peptides from cytosolic proteins and asked whether they should be classified as non-classical neuropeptides (PMID 20383670). In peptide research the word "hemopressin" is often used loosely to cover both the original short peptide and a set of N-terminally extended relatives — collectively referred to as hemopressins or pepcans — that share the same core sequence.

Where the Molecule Comes From

Hemopressin is not a synthetic scaffold designed from scratch; it is a fragment of an endogenous protein. Review articles have described hemopressin and related peptides as hemoglobin-derived signalling molecules that target cannabinoid receptors (PMID 31831183). A separate review framed the discovery of hemopressin as a turning point for the cannabinoid field, because it introduced the idea that a peptide — rather than a lipid such as anandamide — could act at cannabinoid receptors (PMID 33212113). Work on the longer forms characterised pepcan-23 as a pro-peptide of RVD-hemopressin(α), also called pepcan-12, and examined the stability of hemopressins in mice (PMID 33799079).

Terms Used for the Peptide Family

How the Term Is Used in Peptide Research

In the research literature, "hemopressin" functions as shorthand for a probe of the endocannabinoid system. Because cannabinoid receptor pharmacology had been dominated by lipid ligands and synthetic small molecules, a peptide with activity at these receptors offered an alternative chemical starting point, and a review discussed hemopressin peptides as modulators of the endocannabinoid system with potential applications as therapeutic tools (PMID 27748182). A second review examined how hemopressin peptides modulate cannabinoid receptors and how the different family members differ in their pharmacological behaviour (PMID 22884803). The term also appears in studies of peptidomics and protein degradation, where hemopressin is cited as an example of bioactive peptides generated from cytosolic proteins (PMID 20383670).

Practically, that means a paper mentioning hemopressin is usually doing one of three things: characterising receptor binding and signalling in cells or membranes, testing a behavioural or physiological readout in rodents after administration, or reviewing the family as a whole. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment or the use of any substance.

What the Published Literature Reports

Receptor-level work

Receptor pharmacology is the core of the hemopressin literature. A study investigated the receptor binding and functional characteristics of hemopressin(1-7), a shortened version of the parent peptide (PMID 26895730). Review articles summarising this body of work described hemopressin and its extended relatives as peptides that modulate cannabinoid receptors, with different family members behaving differently at the same receptor (PMID 22884803), and a further review placed these signalling molecules within the broader class of neuropeptides targeting cannabinoid receptors (PMID 31831183). Stability is a recurring theme: researchers examined the stability of hemopressins in mice alongside the characterisation of pepcan-23 as the pro-peptide of pepcan-12 (PMID 33799079).

Animal studies

Most in-vivo hemopressin work has been done in rodents. An early study reported an antinociceptive action of hemopressin in experimental hyperalgesia (PMID 15652650). Feeding behaviour has also been examined: one study reported anorexigenic effects induced by RVD-hemopressin(α) administration (PMID 29145068). In the gut, researchers reported that central administrations of hemopressin and related peptides inhibited gastrointestinal motility in mice (PMID 26991932). Specific doses, routes and schedules vary between these experiments and are described within the individual papers rather than summarised here.

Reported Adverse and Unwanted Effects: What Studies Report

The hemopressin literature is not uniformly favourable, and several papers described effects that would be considered unwanted. A rat study reported emotional disorders — anxiety- and depression-related behavioural changes — induced by administration of hemopressin and RVD-hemopressin(α) (PMID 29128806). A separate rat study reported that hemopressin increased penicillin-induced epileptiform activity, an electrophysiological seizure model (PMID 31950838). The inhibition of gastrointestinal motility reported after central administration in mice is also a physiological change rather than a neutral observation (PMID 26991932). These findings come from animal models; the published record described here does not include human safety data.

Limitations of the Evidence

• Animal models only. The behavioural, feeding, pain and seizure-model findings summarised above were reported in rats and mice (PMID 15652650, PMID 31950838).
• Route matters. Some effects were reported specifically after central administration rather than peripheral dosing (PMID 26991932).
• Family-level confusion. Hemopressin, RVD-hemopressin(α) and truncated analogues are distinct molecules with distinct pharmacology, a point emphasised in reviews of the family (PMID 22884803) and in receptor work on hemopressin(1-7) (PMID 26895730).
• Ongoing debate about origin. Whether these hemoglobin fragments represent genuine endogenous signalling molecules or partly reflect sample processing has been discussed in the literature on non-classical neuropeptides (PMID 20383670).

Regulatory Status

Hemopressin and its relatives are laboratory research compounds. They are not approved medicines in the United States or the European Union, and the published work discussed above consists of in-vitro pharmacology and rodent experiments. Reviews describing hemopressin peptides as "potential therapeutic tools" referred to preclinical possibility, not to any authorised product (PMID 27748182).

In Short

Hemopressin is a hemoglobin-derived peptide best known as a peptide ligand of the cannabinoid system, a role that reviews have described as a notable development for cannabinoid pharmacology (PMID 33212113). The published record includes receptor characterisation, reports of antinociception in a hyperalgesia model (PMID 15652650), reduced feeding with RVD-hemopressin(α) (PMID 29145068), and adverse behavioural and seizure-model findings (PMID 29128806).

References

• Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools (Protein and Peptide Letters, 2016)
• Hemopressin as a breakthrough for the cannabinoid field (Neuropharmacology, 2021)
• Modulation of the cannabinoid receptors by hemopressin peptides (Life Sciences, 2013)
• Signaling molecules targeting cannabinoid receptors: Hemopressin and related peptides (Neuropeptides, 2020)
• Hemopressin increases penicillin-induced epileptiform activity in rats (Bratislavske Lekarske Listy, 2020)
• Investigation of receptor binding and functional characteristics of hemopressin(1-7) (Neuropeptides, 2016)
• Emotional disorders induced by Hemopressin and RVD-hemopressin(α) administration in rats (Pharmacological Reports, 2017)
• Hemopressin and other bioactive peptides from cytosolic proteins: are these non-classical neuropeptides? (The AAPS Journal, 2010)
• Anorexigenic effects induced by RVD-hemopressin(α) administration (Pharmacological Reports, 2017)
• Characterization of pepcan-23 as pro-peptide of RVD-hemopressin (pepcan-12) and stability of hemopressins in mice (Advances in Biological Regulation, 2021)
• Antinociceptive action of hemopressin in experimental hyperalgesia (Peptides, 2005)
• Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice (Neurogastroenterology and Motility, 2016)